巣状分節性糸球体硬化症市場 - 競合情勢

2024年には、世界の16カ国で36,000件以上の巣状分節性糸球体硬化症（FSGS）の診断偶発症例が予測されています。現在の市場は、対症療法に使用される薬剤の適応外使用のみに対応しているため、疾患修飾的で効果的な治療の市場には大きなギャップがあります。

FSGSのパイプラインには22の分子があります。フェーズIIIのパイプラインは3つの薬剤で構成され、次いでフェーズIIの薬剤が5つあります。過去10年間、米国はFSGSの臨床試験施設が最も多く、500施設以上でした。過去10年間、北米では買収が主流でした。欧州ではライセンス契約が最も多くなっています。

当レポートでは、世界の巣状分節性糸球体硬化症（FSGS）市場について調査し、疾患の概要とともに、治験動向、パイプライン概要、将来の見通しなどを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 病気の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤の評価

• 主な市販薬
• 作用機序別概要
• 分子タイプ別概要
• 製品プロファイルと売上予測

第5章 価格設定と償還評価

• 年間治療費
• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

• 中期から後期段階のパイプライン薬剤
• 開発段階別概要
• 作用機序別概要
• 分子タイプ別概要
• 薬剤固有の相転移成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症別のPTSRとLoA

第7章 臨床試験の評価

• 実績の概要
• 相別概要
• ステータス別概要
• 進行中および計画中の試験の相別概要
• 仮想コンポーネントの試験
• 地域の試験概要
• 地域別の単一国および多国間試験
• 相別のスポンサー上位20社
• ステータス別のスポンサー上位20社
• エンドポイントステータス別概要
• 人種と民族別概要
• 登録データ
• 治験実施施設上位20カ国
• 世界のトップ20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis therapeutics.

• In 2024, more than 36,000 diagnosed incident cases of FSGS are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for FSGS.
• There's a significant gap in the market for disease modifying and effective treatment as the current market is catered by only the off-label usage of drugs for symptomatic treatment.
• There are 22 molecules in the pipeline for FSGS. The Phase III pipeline consists of three drugs, followed by five drugs in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for FSGS, at more than 500 trial sites.
• In past decade, acquisitions were the predominant type of deal in North America. In Europe, licensing agreements were most frequent deal type.

Scope

GlobalData's Focal Segmental Glomerulosclerosis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer